يعرض 1 - 10 نتائج من 28 نتيجة بحث عن '"Barba Suñol, Pere"', وقت الاستعلام: 1.36s تنقيح النتائج
  1. 1
    رسالة جامعية

    المؤلفون: Barba Suñol, Pere

    المساهمون: University/Department: Universitat Autònoma de Barcelona. Departament de Medicina

    مرشدي الرسالة: Martino Bofarull, Rodrigo, Sierra Gil, Jorge

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  2. 2
    دورية أكاديمية

    مصطلحات موضوعية: Patologia, Salut pública Planificació

    وصف الملف: application/pdf

    العلاقة: Bmj Open, 2023, vol. 13, num. 7; Solano Vercet, Carlos Castro Rebollo, Pedro Pérez Martínez, Antonio López Corral, Lucía Barba Suñol, Pere Kwon, Mi Ortiz, Valentín Sanz Caballer, Jaime Caballero, Ana Carolina Martínez, Joaquín Cedillo, Ángel Sureda, Anna 2023 Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study Bmj Open 13 7; https://hdl.handle.net/10550/89215Test; 161155

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, González-Gil C, Lopes T, Fuster-Tormo F, García-Chica J Institut d’Investigació contra la Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Bellaterra, Spain. Morgades M Departament d’Hematologia Clínica, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Bellaterra, Spain. Zhao R Department of Quantitative Health Sciences and Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA. Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Haematologica;108(4); https://doi.org/10.3324/haematol.2022.281196Test; González-Gil C, Morgades M, Lopes T, Fuster-Tormo F, García-Chica J, Zhao R, et al. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials. Haematologica. 2023 Apr;108(4):969–80.; https://hdl.handle.net/11351/9421Test; 000736413906053

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Rejeski K, Blumenberg V Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament of Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Lopez-Corral L Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain. Kharboutli S Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany. Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Germany. Hernani R Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: HemaSphere;7(4); http://dx.doi.org/10.1097/HS9.0000000000000858Test; Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, et al. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. HemaSphere. 2023 Apr;7(4):e858.; https://hdl.handle.net/11351/9433Test

  5. 5
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ribera J, Granada I, Morgades M Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Bellaterra, Spain. González T Hospital Universitario de Salamanca, Universidad de Salamanca, IBMCC (CSIC/USAL), IBSAL and CIBERONC. Ciudad J Cytometry Service (NUCLEUS) and Department of Medicine, Cancer Research Center (IBMCC-CSIC/ USAL-IBSAL), University of Salamanca, Salamanca. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid. Such E Hematology Department, Hospital Universitari Politècnic La Fe, Valencia. Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: British Journal of Haematology;196(3); https://doi.org/10.1111/bjh.17844Test; Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, et al. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Br J Haematol. 2022 Feb;196(3):670–5.; https://hdl.handle.net/11351/7810Test; 000697597200001

  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Blood & Marrow Transplant Program, Miami Cancer Institute, Miami, Florida, USA. Iacoboni G, Carpio C, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Penack O Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. German Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany. Bücklein V Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Jentzsch L Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal for ImmunoTherapy of Cancer;10(5); http://dx.doi.org/10.1136/jitc-2021-004475Test; Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May;10(5):e004475.; https://hdl.handle.net/11351/8036Test; 000797594100008

  10. 10
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Fernández-Naval C, Pumarola T, Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Villacampa G Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martinez-Gallo M, Hernández M Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cabirta A, Catalá E, Valentín M, Marín-Niebla A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Orfao A Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. Campins M Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ruiz-Camps I Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;6(3); https://doi.org/10.1182/bloodadvances.2021006101Test; Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774–84.; https://hdl.handle.net/11351/8614Test; 000754263400007